Clora reported that Elpoltersen suppressed TTR production by roughly 77% in ATTR-CM patients, exactly what it was designed to do.
Public source
Publisher name
Public post
A drug worked. A trial failed. Those are not the same thing. Elpoltersen suppressed TTR production by roughly 77% in ATTR-CM patients, exactly what it was designed to do…
Company
Clora
The best place to discover, build, and manage on-demand life science teams.
- Industry
- Technology, Information and Internet
- Location
- Boston, US
- Company size
- 11–50 employees
About Clora
Clora is an intelligent platform that matches life science companies with flexible, on-demand expertise. Clora is faster, more cost-efficient, and yields higher quality on-demand talent compared to traditional recruitment methods. Clora has access to the entire global network of life science consultants, with decades of combined industry experience across dozens of roles from companies like Merck, Johnson & Johnson, Pfizer, Novartis, and the FDA. Clora was built by industry veterans who have experienced firsthand the pain and costs associated with staffing projects with the right talent. With Clora, you simply post a project, identifying your unique requirements and our proprietary technology will select up to 3 candidates that meet the specific needs of your project. We have a 100% success rate in matching candidates to projects, within days. Posting a project only takes minutes and is risk free. Post a project today.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
ScienTek
ScienTek showed that TIGRa matched or outperformed CRISPR activators on six out of nine therapeutic genes tested.
Research & Knowledge
BridgeBio
BridgeBio published a new publication in the American Heart Association's Journal of the American Heart Association regarding the joint assessment of sTTR and NT-proBNP for ATTRCM.
Research & Knowledge
Fortrea
Fortrea published results from an early-stage trial showing that a single-dose experimental gene-editing therapy reduced bad cholesterol and triglycerides in patients for at least one year.
Research & Knowledge
Raina Biosciences
Raina Biosciences published GEMORNA in Science Magazine one year ago and is now powering over 30 mRNA therapeutic programs across applications.
Research & Knowledge
Bionews, Inc.